SARS-CoV-2 Spike Peptide
Reactivité: SARS Coronavirus-2 (SARS-CoV-2)
Hôte: Synthetic
InhA
2 images
(3 références)-
- Antigène Tous les produits SARS-CoV-2 Spike
- SARS-CoV-2 Spike
- Origine
- SARS Coronavirus-2 (SARS-CoV-2)
-
Source
- Synthetic
- Application
- Inhibition Assay (InhA)
- Séquence
- ANQFNSAIGK IQDSLSSTAS ALGKLQDVVN QNAQALNTLV KQ
- Attributs du produit
- 2019-nCov-HR1P
- Pureté
- ≥ 95 %
- Ingrédients
- Each vial contains 100 μg of NET peptide.
-
SARS-CoV-2 Spike peptide
Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
SARS-CoV-2 Spike peptide (Cy5)Reactivité: SARS Coronavirus-2 (SARS-CoV-2) Hôte: Synthetic InhA
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Powder
- Stock
- RT,4 °C,-20 °C
- Stockage commentaire
- Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." dans: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." dans: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." dans: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." dans: Cellular & molecular immunology, (2020) (PubMed).
-
- Antigène
- SARS-CoV-2 Spike
- Synonymes
- E2 Peptide, E2 glycoprotein precursor Peptide, Surface Glycoprotein Peptide, S Peptide
- Classe de substances
- Viral Protein
- Poids moléculaire
- 4386.89
- ID gène
- 43740568
- UniProt
- P0DTC2
-
Vous êtes ici:
